180 related articles for article (PubMed ID: 25456833)
21. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan.
Li C; Zhao X; Wang Y; Yang H; Li H; Li H; Tian W; Yang J; Cui J
Int J Pharm; 2013 Feb; 443(1-2):17-25. PubMed ID: 23318366
[TBL] [Abstract][Full Text] [Related]
22. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
[TBL] [Abstract][Full Text] [Related]
23. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
Freeman BB; Iacono LC; Panetta JC; Gajjar A; Stewart CF
Neuro Oncol; 2006 Apr; 8(2):89-95. PubMed ID: 16461424
[TBL] [Abstract][Full Text] [Related]
24. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
Saito R; Krauze MT; Noble CO; Drummond DC; Kirpotin DB; Berger MS; Park JW; Bankiewicz KS
Neuro Oncol; 2006 Jul; 8(3):205-14. PubMed ID: 16723630
[TBL] [Abstract][Full Text] [Related]
25. Development, Characterization, and Evaluation of SLN-Loaded Thermoresponsive Hydrogel System of Topotecan as Biological Macromolecule for Colorectal Delivery.
Xing R; Mustapha O; Ali T; Rehman M; Zaidi SS; Baseer A; Batool S; Mukhtiar M; Shafique S; Malik M; Sohail S; Ali Z; Zahid F; Zeb A; Shah F; Yousaf A; Din F
Biomed Res Int; 2021; 2021():9968602. PubMed ID: 34285920
[TBL] [Abstract][Full Text] [Related]
26. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.
Serwer LP; Noble CO; Michaud K; Drummond DC; Kirpotin DB; Ozawa T; Prados MD; Park JW; James CD
Neuro Oncol; 2011 Dec; 13(12):1288-95. PubMed ID: 21954443
[TBL] [Abstract][Full Text] [Related]
27. [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 4. Topotecan binds preferably to the GC base pairs of DNA].
Strel'tsov SA; Mikheĭkin AL; Grokhovskiĭ SL; Oleĭnikov VA; Kudelina IA; Zhuze AL
Mol Biol (Mosk); 2002; 36(5):912-30. PubMed ID: 12391856
[TBL] [Abstract][Full Text] [Related]
28. Engineered liposomes bearing camptothecin analogue for tumour targeting:
Saraf S; Jain A; Tiwari A; Verma A; Jain SK
J Liposome Res; 2021 Dec; 31(4):326-341. PubMed ID: 32718195
[TBL] [Abstract][Full Text] [Related]
29. Dynamic, nonsink method for the simultaneous determination of drug permeability and binding coefficients in liposomes.
Fugit KD; Anderson BD
Mol Pharm; 2014 Apr; 11(4):1314-25. PubMed ID: 24628304
[TBL] [Abstract][Full Text] [Related]
30. Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes.
Zhang J; Shi W; Xue G; Ma Q; Cui H; Zhang L
Curr Drug Metab; 2020; 21(11):902-909. PubMed ID: 32851958
[TBL] [Abstract][Full Text] [Related]
31. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
32. Structural photodynamic behavior of topotecan, a potent anticancer drug, in aqueous solutions at different pHs.
di Nunzio MR; Wang Y; Douhal A
J Phys Chem B; 2012 Jul; 116(28):8182-90. PubMed ID: 22712701
[TBL] [Abstract][Full Text] [Related]
33. Excited state proton transfer dynamics of Topotecan inside biomimicking nanocavity.
Koninti RK; Gavvala K; Sengupta A; Hazra P
J Phys Chem B; 2015 Feb; 119(6):2363-71. PubMed ID: 25105353
[TBL] [Abstract][Full Text] [Related]
34. Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers.
Venâncio JH; Andrade LM; Esteves NLS; Brito LB; Valadares MC; Oliveira GAR; Lima EM; Marreto RN; Gratieri T; Taveira SF
J Pharm Pharmacol; 2017 Oct; 69(10):1318-1326. PubMed ID: 28703281
[TBL] [Abstract][Full Text] [Related]
35. [Studies by means of 1H NMR spectroscopy of complex formation of aromatic biologically active compounds with antibiotic topotecan].
Mosunov AA; Kostiukov VV; Evstigneev MP
Ukr Biokhim Zh (1999); 2012; 84(2):61-72. PubMed ID: 22642123
[TBL] [Abstract][Full Text] [Related]
36. Copper-topotecan complexation mediates drug accumulation into liposomes.
Taggar AS; Alnajim J; Anantha M; Thomas A; Webb M; Ramsay E; Bally MB
J Control Release; 2006 Aug; 114(1):78-88. PubMed ID: 16842880
[TBL] [Abstract][Full Text] [Related]
37. Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood.
Hubbard KE; Schaiquevich P; Bai F; Fraga CH; Miller L; Panetta JC; Stewart CF
Biomed Chromatogr; 2009 Jul; 23(7):707-13. PubMed ID: 19277971
[TBL] [Abstract][Full Text] [Related]
38. Sustained-release hydrogels of topotecan for retinoblastoma.
Taich P; Moretton MA; Del Sole MJ; Winter U; Bernabeu E; Croxatto JO; Oppezzo J; Williams G; Chantada GL; Chiappetta DA; Schaiquevich P
Colloids Surf B Biointerfaces; 2016 Oct; 146():624-31. PubMed ID: 27429296
[TBL] [Abstract][Full Text] [Related]
39. pH-sensitive liposomes bearing a chemotherapeutic agent and a natural apoptosis modulator for effective intracellular delivery to the solid tumor.
Saraf S; Jain SK
Drug Deliv Transl Res; 2023 Dec; 13(12):2961-2981. PubMed ID: 37306925
[TBL] [Abstract][Full Text] [Related]
40. Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.
Bączek T; Konieczna L; Belka M; Maciejka-Kapuścińska L; Wiśniewski J; Niedźwiecki M; Balcerska A; Adamkiewicz-Drożyńska E; Wachowiak J
J Pharm Biomed Anal; 2012 Nov; 70():330-6. PubMed ID: 22658903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
